Biotechnology industries
Sinovac Biotech Ltd., a leading biotechnology company in China, has made significant strides in research and development, commercialization, and sales of human vaccines in 2004. The company gained approval for SARS vaccine clinical trials on humans in January 2004 and completed its split flu influenza vaccine clinical trials in April,
Biotechnology industries
Tina S. Nova, a distinguished biotechnology executive, has joined the board of directors at Cyntellect, Inc., a privately held biotechnology company. Nova brings to the table extensive knowledge and experience in operational development, strategic planning, and executive management. Her unique blend of scientific expertise, strategic planning, operations expertise, and fundraising
Biotechnology industries
Amgen, a leading pharmaceutical company, has pledged an unprecedented $18 million in 2005 to support patient assistance programs for patients struggling with cancer or kidney disease. These programs, designed to ensure access to life-saving therapies, are funded by grants to independent non-profit charitable foundations. The increased funding will enable patients
Biotechnology industries
Sangamo BioSciences, Inc. (NASDAQ:SGMO) has teamed up with Pfizer Inc to develop novel technologies for protein production. Under the agreement, Pfizer will fund research at Sangamo's facilities, and the company will utilize its proprietary zinc finger DNA binding protein (ZFP) technology to create enhanced cell lines for
Biotechnology industries
ConjuGon, a biotechnology company focused on developing new treatments for antibiotic-resistant bacterial infections, has strengthened its board of directors with the appointment of Guillermo Herrera. Herrera brings over two decades of experience in the pharmaceutical industry, including senior leadership positions at Abbott Laboratories. His expertise will be crucial in guiding
Biotechnology industries
The National Cancer Institute (NCI) and Alfacell Corporation have entered into a collaboration to pursue the development of RN321, an anti-CD22/RNase immunoconjugate, a promising anti-cancer therapeutic agent. RN321 combines a B-cell specific monoclonal antibody with Onconase, Alfacell's lead investigational drug candidate, creating a potent cytotoxic agent. This
Biotechnology
Scientists at the Jagiellonian University have discovered that Mycobacterium vaccae modulates monocyte-tumor cell interactions, with significant implications for cancer immunotherapy. The study, published in the journal Cancer Immunology Immunotherapy, reveals that Mycobacterium vaccae can prevent or reverse deactivation of monocytes, which occurs when they come into contact with tumor cells.
Biotechnology
Scientists have developed and assessed the performance of IgG and IgM enzyme-linked immunosorbent assays (ELISAs) using a West Nile virus (WNV) recombinant antigen for the detection of WNV- and other flavivirus-specific antibodies. The assays were developed by Focus Technologies and evaluated using serum panels from normal and diseased individuals. The
Biotechnology
A DNA prime/vaccinia virus boost immunization regime has shown promise in eliciting an efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates. This study, conducted by Spanish researchers, analyzed the antigen-specific immune responses triggered in mice by different combinations of vaccine vehicles expressing
Biotechnology
Researchers from the United States have found that parenteral vaccine adjuvants can promote systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. The study aimed to evaluate the ability of adjuvants to augment peptide-specific immune responses. The findings suggest that parenteral vaccine administration in combination with the appropriate
Biotechnology
Researchers have identified the importance of microbial interactions in the biooxidation of pyrite, a key component in the extraction of metals. A study published in Biotechnology and Bioengineering found that mixed cultures of moderately thermophilic acidophiles were more efficient at dissolving pyrite than pure cultures of individual microorganisms. The study
Biotechnology
As the number of antibiotic-resistant bacteria continues to rise, RiboNovix, Inc. is taking a proactive approach by developing new anti-infectives that are less susceptible to drug resistance. The company has secured an exclusive license from Wayne State University for intellectual property based on Dr. Philip Cunningham's development of
